Immune-Checkpoint Inhibitor (ICI) resumption after severe graft injury in a heart transplant recipient with nivolumab-sensitive metastatic melanoma and renal cell carcinoma.

J Heart Lung Transplant

Department of Cardiovascular Medicine, Cardio-Oncology Program, University of Kansas Medical Center, Kansas City, Missouri. Electronic address:

Published: December 2022

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166596	PMC
http://dx.doi.org/10.1016/j.healun.2022.08.004	DOI Listing

Publication Analysis

immune-checkpoint inhibitor

inhibitor ici

ici resumption

resumption severe

severe graft

graft injury

injury heart

heart transplant

transplant recipient

recipient nivolumab-sensitive

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!